In this regard, it is worth mentioning that Garcia et al. have developed a recombinant protein therapeutic approach using a soluble form of human FGFR3 to prevent achondroplasia, which acts as a decoy receptor and prevents FGF from binding to mutant FGFR3.59 This evidence concerns the gene FGFR3 and achondroplasia.